Antiplatelet therapy with clopidogrel versus aspirin in atherosclerotic cardiovascular disease: a systematic review and meta-analysis

Abstract

Background and aims

Whether single antiplatelet therapy (SAPT) with clopidogrel offers superior ischemic efficacy and a more favourable bleeding profile than aspirin in atherosclerotic cardiovascular disease is unclear.

Methods

A systematic search on the main databases Medline, Web of Science, and Embase until April 21, 2024 was performed. Only randomized trials were eligible for this analysis. As primary endpoint we analyzed major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction (MI) and non-fatal stroke. As secondary endpoints we investigated the individual primary endpoints as well as the rate of total and severe bleeding events. The analysis was carried out using the odds ratio (OR) as outcome measure. Due to the expected heterogeneity across studies, a random-effects model was fitted to the data.

Results

In total, 6 randomized trials comprising 33,508 patients (16,824 on clopidogrel, 16,684 on aspirin) were analyzed. Clopidogrel as compared to aspirin significantly reduced MACE (OR 0.85 [95 %CI 0.77–0.94], p < 0.001, I² = 26 %). The reduction was driven by a decrease in non-fatal MI (OR 0.73 [95 %CI 0.60–0.90], p = 0.01, I² = 28 %) and stroke (OR 0.86 [95 %CI 0.74–1.00], p = 0.05, I² = 8 %), without increasing the rates of total (OR 1.04 [95 %CI 0.83–1.31], p = 0.73, I² = 72 %) or severe bleeding (OR 0.89 [95 %CI 0.83–1.18], p = 0.43, I² = 50 %). No effect on all-cause mortality was detectable (OR 0.96 [95 %CI 0.87–1.06], p = 0.41, I² = 0 %).

Conclusion

In patients with atherosclerotic cardiovascular disease, SAPT with clopidogrel is associated with lower MACE rates as compared to aspirin without increasing the risk of bleeding.